SH491 (Compound 33) serves as an antiosteoporosis agent, effectively inhibiting RANKL-induced osteoclast differentiation in bone-marrow-derived monocytes (BMMs) with an IC50 of 11.8 nM. Additionally, SH491 suppresses the expression of genes and proteins related to osteoclastogenesis, specifically TRAP, CTSK, MMP-9, and ATPase v0d2 [1].
Target-Kategorie:
Others
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
